Proteins IL-17F , Human
- Known as:
- Proteins Interleukin-17F , Human
- Catalog number:
- C030
- Product Quantity:
- 10μg
- Category:
- -
- Supplier:
- Novoprotein
- Gene target:
- Proteins IL-17F Human
Related genes to: Proteins IL-17F , Human
- Gene:
- IL17F NIH gene
- Name:
- interleukin 17F
- Previous symbol:
- -
- Synonyms:
- IL-17F, ML-1, ML1
- Chromosome:
- 6p12.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-03-18
- Date modifiied:
- 2019-04-23
Related products to: Proteins IL-17F , Human
Related articles to: Proteins IL-17F , Human
- Psoriasis is a chronic immune-mediated inflammatory disease frequently associated with systemic comorbidities, including an increased prevalence of interstitial lung diseases (ILDs). Progressive fibrosing ILDs are characterized by declining respiratory function and high morbidity, and emerging evidence suggests that type-17 immune pathways may contribute to both psoriatic inflammation and pulmonary fibrosis. Bimekizumab, a monoclonal antibody selectively targeting IL-17A and IL-17F, has demonstrated high efficacy in psoriasis, although its potential impact on fibrotic lung disease remains unclear. We report the case of a 58-year-old man with severe plaque psoriasis and concomitant desquamative interstitial pneumonia (DIP) with features of progressive pulmonary fibrosis. The patient presented with severe restrictive lung disease, reduced diffusing capacity, and exertional desaturation requiring oxygen supplementation. Previous treatments included topical therapies, acitretin, and intermittent systemic corticosteroids, which contributed to worsening skin disease. Bimekizumab was initiated after appropriate screening, resulting in rapid and complete skin clearance by week 12, with no adverse events. Over a 14-month follow-up, a progressive improvement in respiratory function was observed, including increased spirometric parameters, improved diffusing capacity, and enhanced exercise tolerance, with resolution of exertional desaturation and discontinuation of oxygen support during mild activity. No other therapeutic changes were made during this period. Given the role of IL-17 cytokines in inflammation and fibrosis, this observation suggests a potential effect of IL-17A/F inhibition on fibrotic lung processes. This case highlights a possible dual benefit of bimekizumab in patients with psoriasis and concomitant ILD and supports further investigation into shared pathogenic pathways and targeted therapeutic strategies. - Source: PubMed
Publication date: 2026/09/11
Corrà AlbertoMariotti Elena BiancamariaRuffo di Calabria ValentinaMagnatta AlessandroSanna LucaCorti VirginiaDonati MartaBonanni IreneDaher RachelQuintarelli LaviniaRosi ElisabettaVerdelli AliceCaproni Marzia - Psoriasis is a clinically heterogeneous inflammatory dermatosis characterized by diverse subtypes with variable therapeutic responses. While biologic therapies targeting TNF-α, IL-17, IL-23, and IL-36 pathways have transformed disease management, treatment selection remains largely empirical and is not routinely guided by tissue-level immune profiling. In this study, we performed quantitative immunohistochemical analysis of key cytokines, IL-17A, IL-17F, IL-23p19, IL-36γ, and TNF-α, across five psoriasis subtypes (guttate, inverse, palmoplantar, plaque, and pustular) using formalin-fixed paraffin-embedded skin biopsies. Cytokine-positive dermal cell populations were quantified using digital pathology, enabling subtype-specific comparison of inflammatory signatures. Distinct cytokine patterns were observed across subtypes. Pustular psoriasis demonstrated a prominent IL-17F and IL-36γ-dominant profile, whereas plaque psoriasis exhibited broad cytokine expression with relative IL-17A predominance. Palmoplantar psoriasis showed a mixed IL-17/IL-36 signature, while guttate and inverse subtypes displayed comparatively attenuated inflammatory profiles. Because cytokine expression was quantified within the dermal compartment, these findings should be interpreted as dermal inflammatory patterns rather than as measures of total tissue cytokine expression, particularly for IL-36γ, which is also strongly associated with keratinocyte-derived epidermal responses. These findings provide tissue-level evidence of immunologic heterogeneity across psoriasis subtypes and support the concept of cytokine-driven disease endotypes. Biopsy-based cytokine profiling may represent a promising, hypothesis-generating approach for characterizing lesion-specific inflammatory patterns and potentially informing individualized therapeutic strategies, although prospective studies linking tissue profiles with treatment response are required to establish clinical utility. - Source: PubMed
Publication date: 2026/09/24
Soto VictoriaMufarrej SammyaGaumond Simonetta IPrati Laura Dalla RosaRongioletti FrancoJozic IvanRomanelli Paolo - Single nucleotide polymorphisms (SNPs) in the interleukin-17F (IL-17F) gene may modulate inflammatory responses, with distinct effects on inflammation and tumour progression. Helicobacter pylori infection, a Group 1 carcinogen, is strongly associated with gastric cancer (GC) development. This study investigated the influence of IL-17F SNPs rs763780 (T>C), rs2397084 (T>C), rs9382084 (G>T), and rs12203582 (G>A) on GC susceptibility, considering H. pylori infection status. A total of 301 gastric biopsy samples were classified into the control (n = 95), gastritis (n = 112), and cancer (n = 94) groups. Helicobacter pylori detection and SNP genotyping were performed by quantitative real-time PCR (qPCR). Statistical analyses included Hardy-Weinberg equilibrium (HWE), Fisher's exact test, haplotype analysis, and genetic models using the SNPStats software, with sensitivity analysis performed in G*Power. All SNPs conformed to HWE except for rs763780. The T/C genotype and C allele of rs763780 were more frequent in the control group, indicating a protective effect (OR = 0.35; 95% CI = 0.14-0.91; p = 0.04). In contrast, the G/G genotype of rs9382084 (OR = 2.29; 95% CI = 1.02-5.13; p = 0.039) and the A/A genotype of rs12203582 (OR = 3.01; 95% CI = 1.01-8.93; p = 0.047) were associated with increased GC risk. No significant association was found for rs2397084. Haplotype analysis identified the rs763780-C/rs2397084-T/rs9382084-T/rs12203582-G haplotype as protective against GC (OR = 0.30; 95% CI = 0.10-0.86; p = 0.026). Stratified analysis according to H. pylori infection status suggested specific associations between SNPs rs763780, rs2397084, and rs12203582 and the risk of GC. These findings suggest that IL-17F gene SNPs influence GC susceptibility, exerting protective or risk effects depending on the specific polymorphism and its interaction with H. pylori infection. - Source: PubMed
Publication date: 2026/09/17
Nagahara MikaelaFredi Bruno MariBrandt Fabricio AbdallaFonseca Alanis Dos SantosCoelho Milena MilaniGirolli DanielliChen Elizabeth SuchiBarbosa Monica SantiagoPayao Spencer Luiz MarquesRasmussen Lucas Trevizani - To evaluate the impact of bimekizumab, a dual IL-17A and IL-17F inhibitor, on sacroiliac joint (SIJ) and spine inflammation/structural damage in axSpA using MRIs/radiographs from the phase 3 studies BE MOBILE 1 (nr-axSpA) and 2 (r-axSpA) and their open-label extension (OLE). - Source: PubMed
Publication date: 2026/09/14
Maksymowych Walter PRamiro SofiaPoddubnyy DenisBaraliakos XenofonLambert Robert G WMassow UteVaux TomPrajapati ChetanMarten Alexanderde Peyrecave NatashaØstergaard Mikkel - Primary mediastinal large B-cell lymphoma (PMBCL) predominantly affects female adolescents and young adults. It displays an immune-privileged phenotype and demonstrates the involvement of key cytokine signaling pathways, including increased expression of Thymus and activation-regulated chemokine (TARC/CCL17). Currently, there is a lack of established markers for stratification. We studied plasma concentrations of 24 cytokines at diagnosis in a large population-based pediatric cohort of 62 patients with PMBCL. Compared to a group of age-matched patients with other types of lymphoma in long-term remission and healthy individuals (n=26), we detected elevated concentrations of CCL4, CCL17, interleukin (IL)-6, CXCL8, CXCL9, CXCL10, and CXCL11. The median CCL17 level was 1695 pg/ml (IQR, 642-3142) in patients with PMBCL compared to 81 pg/ml (IQR, 41-190) in controls (p < 0.0001). Concentrations of CCL17, CXCL9, and CXCL10 significantly correlated with mediastinal tumor volume (MTV) and lactate dehydrogenase activity (LDH) but were not associated with event-free survival (EFS). Concentrations of IL-17F and IL-22 were inversely correlated with LDH and MTV. Elevated IL-6, IL-10, IL-17A, and IL-22 were significantly correlated with inferior EFS in a subgroup of 50 patients uniformly treated with dose-adjusted EPOCH with rituximab. Although based on a limited number of events, IL-6 showed the strongest association with outcome (hazard ratio of 6.8 (95%-CI, 1.5-30.9). In summary, pretreatment cytokine levels in patients with PMBCL reveal distinct patterns associated with tumor burden (CCL17, CXCL9, CXCL10) and outcome (IL-6, IL-10, IL-17A, IL-22). - Source: PubMed
Publication date: 2026/09/10
Nipper MalteDamm-Welk ChristineShepheard WillOschlies IlskeKlapper WolframBurkhardt BirgitWoessmann WilhelmKnörr Fabian